Article : BIOD market cap 100 Million In a $10 Billion Industry. article link.
| By: Scott Matusow Article : Our BioPharma Catalyst Feature Pick: Biodel
Biodel (BIOD) is a biopharmaceutical company that focuses on the development and specialization of treatments for diabetes. Biodel's leading drug candidate is BIOD-123, which is an ultra-rapid acting insulin formulation. Biodel has recently been gaining a lot of attention because it has a market cap of under $100M, while the global diabetes market is worth over $10B.